A Randomized, Double-blind, Placebo-controlled Study of an Oral, Extended-release Formulation of Phentermine/topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults

Overview

Journal Sleep

Publisher Oxford University Press

Specialty Psychiatry

Date 2012 Nov 2

PMID 23115402

Citations 43

Authors

David H Winslow

Charles H Bowden

Karen P DiDonato

Pamela A McCullough

Affiliations

Soon will be listed here.

Abstract

Study Objectives: To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults.

Design: This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment periods. Overnight polysomnography was performed at baseline, Week 8, and Week 28.

Setting: Single-center study conducted from August 2008 to September 2009.

Participants: Forty-five subjects with moderate to severe OSA not receiving positive airway pressure (PAP) treatment with body mass index of 30-40 kg/m(2).

Interventions: Subjects were randomized to receive placebo (n = 23) or phentermine 15 mg plus extended-release topiramate 92 mg (n = 22). Both groups received lifestyle-modification counseling.

Measurements And Results: Primary endpoint, change in apnea-hypopnea index (AHI), significantly favored phentermine 15 mg plus extended-release topiramate 92 mg (-31.5 events/h, 95% CI: -40.0, -22.9) over placebo (-16.6 events/h, 95% CI: -25.0, -8.2) at Week 28 (P =0.0084). At Week 28, there was a 10.2% (95% CI: -12.7, -7.6; 10.8 kg, 95% CI: -13.5, -8.0) mean decrease in weight in the phentermine 15 mg plus extended-release topiramate 92 mg group compared with 4.3% (95% CI: -6.6, -2.0; 4.7 kg, 95% CI: -7.2, -2.2) in the placebo group (P = 0.0006) and a positive, significant (P = 0.0003) correlation between percent change in weight and change in AHI. Significant improvements in overnight oxygen saturation and reduction in blood pressure compared with placebo were observed. Phentermine 15 mg plus extended-release topiramate 92 mg was well tolerated with low adverse event rates.

Conclusions: Phentermine 15 mg plus extended-release topiramate 92 mg induced significant weight reductions and concomitant improvements in OSA and related symptoms vs placebo. This suggests weight loss mediated by phentermine 15 mg plus extended-release topiramate 92 mg may be useful in treatment of moderate to severe OSA in obese subjects unable or unwilling to comply with PAP treatment.

Citing Articles

Weight Loss for Obstructive Sleep Apnea: Pharmacological and Surgical Management.

Kim B, Choi J J Rhinol. 2024; 30(1):1-5.

PMID: 39664699 PMC: 11524361. DOI: 10.18787/jr.2023.00010.

First-Generation Anti-Obesity Medications.

Barenbaum S, Aras M Diabetes Spectr. 2024; 37(4):296-302.

PMID: 39649696 PMC: 11623038. DOI: 10.2337/dsi24-0003.

Tackling obstructive sleep apnea with pharmacotherapeutics: expert guidance.

Harding C, Fuentes A, Malhotra A Expert Opin Pharmacother. 2024; 25(8):1019-1026.

PMID: 38913403 PMC: 11227253. DOI: 10.1080/14656566.2024.2365329.

Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis.

Malhotra A, Heilmann C, Banerjee K, Dunn J, Bunck M, Bednarik J Sleep Med. 2024; 121:26-31.

PMID: 38908268 PMC: 11330732. DOI: 10.1016/j.sleep.2024.06.014.

An algorithm for the use of anti-obesity medications.

Dehghani F, Ali Ahmadi M, Hefner M, Kudchadkar G, Najam W, Nateqi M Nutr Diabetes. 2024; 14(1):20.

PMID: 38637506 PMC: 11026374. DOI: 10.1038/s41387-024-00278-2.

References

Johns M . Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992; 15(4):376-81. DOI: 10.1093/sleep/15.4.376. View

Young T, Finn L, Peppard P, Szklo-Coxe M, Austin D, Nieto F . Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008; 31(8):1071-8. PMC: 2542952. View

Wolk R, Shamsuzzaman A, Somers V . Obesity, sleep apnea, and hypertension. Hypertension. 2003; 42(6):1067-74. DOI: 10.1161/01.HYP.0000101686.98973.A3. View

Johns M . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-5. DOI: 10.1093/sleep/14.6.540. View

Tasali E, Ip M . Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc. 2008; 5(2):207-17. DOI: 10.1513/pats.200708-139MG. View

Sadatsafavi M, Marra C, Ayas N, Stradling J, Fleetham J . Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea. Sleep Breath. 2009; 13(3):241-52. DOI: 10.1007/s11325-009-0248-4. View

Gadde K, Allison D, Ryan D, Peterson C, Troupin B, Schwiers M . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774):1341-52. DOI: 10.1016/S0140-6736(11)60205-5. View

Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View

Schwartz A, Patil S, Laffan A, Polotsky V, Schneider H, Smith P . Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc. 2008; 5(2):185-92. PMC: 2645252. DOI: 10.1513/pats.200708-137MG. View

10.

Tojima H, KUNITOMO F, Kimura H, Tatsumi K, Kuriyama T, Honda Y . Effects of acetazolamide in patients with the sleep apnoea syndrome. Thorax. 1988; 43(2):113-9. PMC: 1020752. DOI: 10.1136/thx.43.2.113. View

11.

Haines K, Nelson L, Gonzalez R, Torrella T, Martin T, Kandil A . Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery. 2007; 141(3):354-8. DOI: 10.1016/j.surg.2006.08.012. View

12.

Tuomilehto H, Seppa J, Partinen M, Peltonen M, Gylling H, Tuomilehto J . Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 2008; 179(4):320-7. DOI: 10.1164/rccm.200805-669OC. View

13.

Jick H, Vasilakis C, Weinrauch L, Meier C, Jick S, Derby L . A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998; 339(11):719-24. DOI: 10.1056/NEJM199809103391102. View

14.

Chowdhuri S . Continuous positive airway pressure for the treatment of sleep apnea. Otolaryngol Clin North Am. 2007; 40(4):807-27. DOI: 10.1016/j.otc.2007.04.011. View

15.

Shamsuzzaman A, Gersh B, Somers V . Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003; 290(14):1906-14. DOI: 10.1001/jama.290.14.1906. View

16.

Espeland L, Hogevold H, Stenvik A . A 3-year patient-centred follow-up of 516 consecutively treated orthognathic surgery patients. Eur J Orthod. 2007; 30(1):24-30. DOI: 10.1093/ejo/cjm081. View

17.

Hamidovic A, Childs E, Conrad M, King A, de Wit H . Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug Alcohol Depend. 2010; 109(1-3):175-80. PMC: 2875349. DOI: 10.1016/j.drugalcdep.2009.12.029. View

18.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M . A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004; 28(11):1399-410. DOI: 10.1038/sj.ijo.0802783. View

19.

Caples S, Gami A, Somers V . Obstructive sleep apnea. Ann Intern Med. 2005; 142(3):187-97. DOI: 10.7326/0003-4819-142-3-200502010-00010. View

20.

Flemons W . Clinical practice. Obstructive sleep apnea. N Engl J Med. 2002; 347(7):498-504. DOI: 10.1056/NEJMcp012849. View